Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer.

Scott T TagawaShankar VallabhajosulaPaul J ChristosYuliya S JhanwarJaspreet S BatraLinda LamJoseph OsborneHimisha BeltranAna M MolinaStanley J GoldsmithNeil H BanderDavid M Nanus

Published in: Cancer (2019)

Fractionated administration of 177 Lu-J591 allowed higher cumulative radiation dosing. The frequency and depth of PSA decrease, overall survival, and toxicity (dose-limiting myelosuppression) increased with higher doses.

Keyphrases

monoclonal antibody
prostate cancer
squamous cell carcinoma
small cell lung cancer
oxidative stress
open label
brain metastases
optical coherence tomography
benign prostatic hyperplasia
pet imaging
radiation induced
randomized controlled trial
free survival
radiation therapy